Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients - Top-Institutions - MDSpire

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

  • By

  • Elisa Melón-Ardanaz

  • Marisol Veny

  • Ana M Corraliza

  • Victoria Gudiño

  • Alba Garrido-Trigo

  • Ángela Sanzo-Machuca

  • Marc Buendia

  • Miriam Esteller

  • Lisseth Robbins-Moreno

  • Maite Rodrigo

  • M Carme Masamunt

  • Ángel Giner

  • Marta Gallego

  • Ingrid Ordás

  • Agnès Fernández-Clotet

  • Berta Caballol

  • Ángel Corbí

  • Bram Verstockt

  • Severine Vermeire

  • Julian Panés

  • Elena Ricart

  • Azucena Salas

  • May 5, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

  • #2

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Molecular Medicine

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

  • #4

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, CA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Molecular and Cellular Biology

  • #5

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Research

Original Source(s)

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

  • by Elisa Melón-Ardanaz, Marisol Veny, Ana M Corraliza, Victoria Gudiño, Alba Garrido-Trigo, Ángela Sanzo-Machuca, Marc Buendia, Miriam Esteller, Lisseth Robbins-Moreno, Maite Rodrigo, M Carme Masamunt, Ángel Giner, Marta Gallego, Ingrid Ordás, Agnès Fernández-Clotet, Berta Caballol, Ángel Corbí, Bram Verstockt, Severine Vermeire, Julian Panés, Elena Ricart, Azucena Salas

  • May 5, 2025

Related Content

Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease

The innovation trap: How pharma weaponizes a word to extend monopolies

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists